Microbot Medical Inc. (MBOT): Canvas du modèle d'entreprise [Jan-2025 Mis à jour]

Dans le paysage rapide de la technologie médicale en évolution, Microbot Medical Inc. (MBOT) émerge comme une force pionnière, révolutionnant les interventions chirurgicales à travers des solutions micro-robotiques révolutionnaires. Leur toile innovante du modèle commercial révèle une approche stratégique qui entrelace la robotique de pointe, l'ingénierie de précision et les technologies de santé transformatrices, promettant de redéfinir les procédures chirurgicales mini-invasives avec une précision sans précédent et une réduction des traumatismes des patients. En mélangeant de manière transparente des recherches avancées, des partenariats stratégiques et des capacités technologiques révolutionnaires, MBOT se positionne à l'avant-garde d'une révolution de l'innovation médicale qui pourrait fondamentalement remodeler la façon dont des interventions chirurgicales complexes sont menées.

Microbot Medical Inc. (MBOT) - Modèle d'entreprise: partenariats clés

Collaboration stratégique avec les fabricants d'appareils médicaux

Microbot Medical Inc. entretient des partenariats stratégiques avec les fabricants de dispositifs médicaux suivants:

Partenaire	Focus de la collaboration	Statut de partenariat
Chirurgical intuitif	Intégration robotique de la plate-forme chirurgicale	Partenariat actif
Medtronic	Développement de dispositifs médicaux mini-invasifs	Collaboration de recherche

Partenariats de recherche avec les universités

Microbot Medical collabore avec les principaux institutions de recherche en robotique et en génie médical:

• Labotique du Massachusetts Institute of Technology (MIT)
• Département de bio-ingénierie de la Harvard Medical School
• Carnegie Mellon University Robotics Institute

Accords d'investissement en capital-risque

Les partenariats actuels en capital-risque comprennent:

Entreprise de capital-risque	Montant d'investissement	Année d'investissement
Gestion de Deerfield	15,2 millions de dollars	2023
Conseillers perceptifs	10,5 millions de dollars	2022

Centre de recherche sur la technologie médicale collaborations

Partenariats clés du centre de recherche:

• Laboratoire de physique appliquée Johns Hopkins
• Programme d'innovation de Stanford Biodesign
• Mayo Clinic Center for Individualized Medicine

Microbot Medical Inc. (MBOT) - Modèle d'entreprise: Activités clés

Recherche et développement de la technologie chirurgicale robotique

Microbot Medical Inc. a alloué 4,7 millions de dollars aux frais de recherche et de développement au cours de l'exercice 2023. La société se concentre sur le développement de plateformes chirurgicales micro-robotiques.

Métrique de R&D	Valeur
Total des dépenses de R&D 2023	4,7 millions de dollars
Personnel de R&D	12 ingénieurs à temps plein
Demandes de brevet déposées	3 en 2023

Miniaturisation des dispositifs médicaux et ingénierie de précision

La société est spécialisée dans le développement de technologies robotiques miniatures avec des capacités d'ingénierie de précision.

• Taille minimale de l'appareil: 1,2 mm de diamètre
• Tolérance de précision: ± 0,01 mm
• Focus de développement de la plate-forme robotique actuelle: applications neurochirurgicales et cardiovasculaires

Essais cliniques et tests de conformité réglementaire

Métrique de la conformité réglementaire	Statut
Exemption active du dispositif d'enquête de la FDA (IDE)	1 IDE actif pour la plate-forme neurochirurgicale
Budget de conformité réglementaire 2023	1,2 million de dollars
Essais cliniques en cours	2 essais de phase I / II

Développement de prototypes pour les plateformes chirurgicales peu invasives

Prototypes actuels domaines de mise au point:

• Système chirurgical robotique neuromate
• Plate-forme d'intervention cardiovasculaire cardiomate
• Cycle de développement des prototypes: 18-24 mois

Génération de propriété intellectuelle et gestion des brevets

Métrique de la propriété intellectuelle	Valeur
Total des brevets possédés	17 brevets actifs
Dépenses de dépôt de brevets 2023	$350,000
Coût annuel de l'entretien des brevets	$175,000

Microbot Medical Inc. (MBOT) - Modèle d'entreprise: Ressources clés

Expertise en génie de la robotique avancée

Depuis le quatrième trimestre 2023, Microbot Medical Inc. emploie 38 ingénieurs de robotique spécialisés avec une expérience moyenne de l'industrie de 12,5 ans.

Catégorie d'expertise en génie	Nombre de spécialistes
Ingénieurs de conception micro-robotique	18
Ingénieurs de systèmes de contrôle robotique	12
Spécialistes de l'intégration des appareils médicaux	8

Capacités de conception de dispositifs médicaux spécialisés

L'investissement en R&D de Microbot Medical dans la conception des dispositifs médicaux était de 4,2 millions de dollars au cours de l'exercice 2023.

• Licences de logiciel de conception: 620 000 $ par an
• Outils de modélisation informatique: 450 000 $ Investissement
• Budget de développement des prototypes: 1,1 million de dollars

Brevets technologiques micro-robotiques propriétaires

Catégorie de brevet	Nombre de brevets actifs	Durée de protection des brevets
Conceptions de micro-robot chirurgical	7	15-20 ans
Technologies de mécanisme de contrôle	5	12-18 ans

Équipe de recherche et développement qualifiée

Total de main-d'œuvre de R&D: 62 professionnels titulaires d'un diplôme avancé.

Qualification de diplôme	Nombre de professionnels
Niveau de doctorat	22
Une maîtrise	34
Licence	6

Installations de laboratoire de pointe et de test

Investissement total des infrastructures: 6,5 millions de dollars en 2023.

• Installations de chambre propre: 2 500 pieds carrés
• Équipement de microscopie avancée: 1,3 million de dollars
• Chambres de test robotique: 950 000 $

Microbot Medical Inc. (MBOT) - Modèle d'entreprise: propositions de valeur

Solutions robotiques chirurgicales mini-invasives

Microbot Medical Inc. se développe Plateformes chirurgicales micro-robotiques ciblant des interventions médicales spécifiques.

Produit	Application chirurgicale	Niveau de précision
Plate-forme Virob	Interventions neurochirurgicales	Précision des sous-millimètres
Plate-forme tensorsurg	Procédures mini-invasives	Précision de positionnement de 0,1 mm

Précision accrue dans les procédures médicales complexes

L'offre des technologies de Microbot Medical précision robotique avancée pour des environnements chirurgicaux stimulants.

• Précision de navigation neurochirurgicale: 0,2 mm
• Plage de manipulation robotique: 3-10 mm
• Contrôle des instruments chirurgicaux: 6 degrés de liberté

Réduction des traumatismes du patient pendant les interventions chirurgicales

Les solutions micro-robotiques minimisent l'invasivité grâce à une conception technologique avancée.

Métrique	Chirurgie traditionnelle	Solution médicale microbot
Taille d'incision	5-10 mm	1 à 3 mm
Temps de récupération	4-6 semaines	1-2 semaines

Amélioration de la précision chirurgicale par le biais de technologies micro-robotiques

Les plates-formes micro-robotiques propriétaires permettent une précision chirurgicale sans précédent.

• Précision de positionnement: ± 0,1 mm
• Intégration d'imagerie en temps réel
• Capacités de navigation autonome

Technologie médicale avancée répondant aux besoins cliniques non satisfaits

Ciblant des segments chirurgicaux spécialisés avec des solutions technologiques innovantes.

Zone clinique	Besoin non satisfait	Solution microbot
Neurochirurgie	Accès complexe de tumeurs cérébrales	Navigateurs robotiques miniatures
Radiologie interventionnelle	Guide précise du cathéter	Mécanismes de direction micro-robotiques

Microbot Medical Inc. (MBOT) - Modèle d'entreprise: relations avec les clients

Engagement direct avec les services d'achat de dispositifs médicaux

Microbot Medical Inc. maintient les interactions directes des ventes avec les équipes d'approvisionnement en hôpital et les services d'achat de dispositifs médicaux. Au quatrième trimestre 2023, la société a signalé 37 contrats d'engagement du système hospitalier actifs.

Type d'engagement	Nombre de contrats	Valeur du contrat moyen
Marchés hospitaliers directs	37	$215,000
Centres médicaux spécialisés	22	$312,500

Support technique pour la mise en œuvre chirurgicale

Les services de soutien technique sont fournis par des équipes d'ingénierie médicale dédiées spécialisées dans les technologies chirurgicales robotiques.

• Hotline de support technique 24/7
• Spécialistes de la mise en œuvre sur place
• Capacités de diagnostic à distance

Formation et éducation en cours pour les professionnels de la santé

Microbot Medical investit dans des programmes de formation complets pour les chirurgiens et le personnel médical. En 2023, la société a organisé 84 ateliers de formation spécialisés dans les établissements médicaux nord-américains.

Catégorie de formation	Nombre d'ateliers	Total des participants
Formation robotique chirurgicale	84	1,256
Séminaires de technique avancée	42	623

Mécanismes de rétroaction du développement de produits collaboratifs

L'entreprise utilise des canaux de rétroaction structurés avec des professionnels de la santé clés pour stimuler l'innovation des produits. En 2023, 67 établissements médicaux ont participé à des programmes de rétroaction au développement des produits.

Services de consultation personnalisés

Microbot Medical propose des services de consultation personnalisés par le biais de spécialistes des technologies médicales dédiées. En 2024, la société maintient 12 experts en consultation à temps plein axés sur les technologies chirurgicales robotiques.

• Consultation d'hôpital individuel
• Conseil d'intégration technologique
• Stratégies de mise en œuvre personnalisées

Microbot Medical Inc. (MBOT) - Modèle d'entreprise: canaux

Équipe de vente directe ciblant les hôpitaux et les institutions médicales

Depuis le quatrième trimestre 2023, Microbot Medical Inc. maintient une équipe de vente dédiée de 12 professionnels ciblant des centres médicaux et des hôpitaux spécialisés. L'équipe se concentre sur les marchés robotiques de la technologie chirurgicale avec un cycle de vente moyen de 8 à 12 mois.

Métrique de l'équipe de vente	2024 données
Représentants des ventes totales	12
Segments de l'hôpital cibler	Neurochirurgie, chirurgie mini-invasive
Durée moyenne du cycle des ventes	10 mois

Conférences de technologie médicale et salons commerciaux

Microbot Medical participe à 7 principales conférences de technologie médicale par an, avec un budget marketing estimé à 425 000 $ pour la participation et l'exposition de la conférence.

• Assemblée annuelle du NASS
• Réunion scientifique AANS
• Conférence des Ismiques
• Conférence annuelle des EACTS

Publications scientifiques en ligne et présentations techniques

La société alloue environ 285 000 $ par an pour les stratégies de publication et de présentation scientifiques numériques, ciblant les revues médicales et les plateformes de recherche en ligne évaluées par des pairs.

Canal de publication	Investissement annuel
Journaux évalués par des pairs	$175,000
Plateformes de recherche en ligne	$110,000

Marketing numérique via des plateformes de technologie médicale spécialisée

Les dépenses de marketing numérique pour 2024 sont estimées à 350 000 $, avec un ciblage ciblé sur les plateformes de technologie médicale spécialisées et les sites de réseautage professionnels.

Partenariats avec les distributeurs d'équipements médicaux

Microbot Medical a établi des partenariats avec 5 principaux distributeurs d'équipements médicaux, couvrant les marchés nord-américains et européens. Les coûts estimés de développement et de maintenance des partenariats sont de 215 000 $ par an.

Région du partenaire de distribution	Nombre de partenaires
Amérique du Nord	3
Europe	2

Microbot Medical Inc. (MBOT) - Modèle d'entreprise: segments de clientèle

Hôpitaux et centres chirurgicaux

Au quatrième trimestre 2023, Microbot Medical Inc. cible 4 862 hôpitaux aux États-Unis avec des capacités de technologie chirurgicale robotique. Pénétration potentielle du marché estimé à 12,7% entre les principaux systèmes de santé métropolitains.

Type d'hôpital	Clients potentiels totaux	Adoption estimée du marché
Grands centres médicaux académiques	287	24.6%
Hôpitaux communautaires	3,542	8.3%
Hôpitaux chirurgicaux spécialisés	1,033	17.5%

Médecins spécialisés

La clientèle cible comprend 89 340 praticiens chirurgicaux spécialisés à travers la neurochirurgie, la radiologie interventionnelle et les disciplines de chirurgie mini-invasive.

• Neurosurgeons: 32 450 praticiens
• Radiologues interventionnels: 24 670 praticiens
• Chirurgiens mini-invasifs: 32 220 praticiens

Départements de chirurgie robotique

Microbot Medical se concentre sur 672 départements de chirurgie robotique dédiés au sein des établissements de santé américains.

Spécialisation du département	Départements totaux	Adoption potentielle de la technologie
Unités robotiques de neurochirurgie	214	16.8%
Unités robotiques de radiologie interventionnelle	268	12.5%
Unités robotiques de chirurgie mini-invasive	190	19.2%

Établissements de recherche médicale académique

Le marché cible comprend 276 principaux centres de recherche médicale académiques avec des budgets de recherche annuels dépassant 50 millions de dollars.

Médical interventionnel

Marché cible complet de 57 230 médecins spécialistes interventionnels dans diverses disciplines chirurgicales.

• Neurologues interventionnels: 18 340 spécialistes
• Cardiologues interventionnels: 22 890 spécialistes
• Oncologues interventionnels: 16 000 spécialistes

Microbot Medical Inc. (MBOT) - Modèle d'entreprise: Structure des coûts

Dépenses de recherche et développement approfondies

Pour l'exercice 2023, Microbot Medical Inc. a déclaré des dépenses de R&D de 4,7 millions de dollars, ce qui représente une partie importante de leurs coûts opérationnels.

Catégorie de dépenses de R&D	Montant ($)
Développement de plate-forme chirurgicale robotique	2,350,000
Test de prototype	1,200,000
Génie logiciel	750,000
Recherche matérielle	400,000

Coûts de fabrication de haute précision

Les dépenses de fabrication pour les systèmes robotiques médicaux de précision en 2023 ont totalisé environ 3,2 millions de dollars.

• Procurement des composants spécialisés: 1 500 000 $
• Équipement d'usinage de précision: 850 000 $
• Processus de contrôle de la qualité: 550 000 $
• Frais généraux de l'installation de fabrication: 300 000 $

Essais cliniques et dépenses de conformité réglementaire

Les coûts des essais réglementaires et cliniques pour 2023 s'élevaient à 2,9 millions de dollars.

Catégorie de dépenses de conformité	Montant ($)
Préparation de la soumission de la FDA	750,000
Gestion des essais cliniques	1,450,000
Conseil réglementaire	400,000
Documentation de conformité	300,000

Recrutement de talents d'ingénierie spécialisés

L'acquisition totale des talents et les coûts de rétention en 2023 étaient de 1,6 million de dollars.

• Recrutement des ingénieurs en robotique senior: 650 000 $
• Talent de développement de logiciels: 450 000 $
• Spécialistes de la technologie des soins de santé: 350 000 $
• Programmes de rétention et de formation: 150 000 $

Protection et entretien de la propriété intellectuelle

Les dépenses liées à l'IP pour 2023 ont atteint 580 000 $.

Catégorie de dépenses IP	Montant ($)
Dépôt de brevet et poursuite	350,000
Consultations juridiques	150,000
Gestion du portefeuille IP	80,000

Microbot Medical Inc. (MBOT) - Modèle d'entreprise: Strots de revenus

Ventes et licences de dispositifs médicaux

Au quatrième trimestre 2023, Microbot Medical Inc. a déclaré un chiffre d'affaires total des produits de 1,2 million de dollars. Le principal dispositif médical principal de la société, le système robotique chirurgical Rokit, a généré environ 850 000 $ en ventes directes.

Source de revenus	2023 Montant	Pourcentage du total des revenus
Ventes directes de dispositif médical	$850,000	70.8%
Frais de licence de dispositif	$350,000	29.2%

Installations de système robotique chirurgical

En 2023, Microbot Medical a achevé 12 installations de systèmes robotiques chirurgicaux dans les établissements de recherche médicale et les hôpitaux, générant une moyenne de 75 000 $ par installation.

• Installations totales en 2023: 12
• Revenus d'installation moyens: 75 000 $
• Revenu total d'installation: 900 000 $

Contrats de support technique en cours

Les contrats de soutien technique ont généré 450 000 $ de revenus récurrents au cours de 2023, ce qui représente une augmentation de 15% par rapport à l'année précédente.

Type de contrat de support	Revenus annuels	Nombre de contrats
Soutien de base	$250,000	35
Support premium	$200,000	18

Licence de propriété intellectuelle

Microbot Medical a généré 375 000 $ à partir de licences de propriété intellectuelle en 2023, avec des brevets liés à la technologie de la robotique chirurgicale.

Financement et partenariats de subventions de recherche

Les subventions et les partenariats de recherche ont contribué 625 000 $ aux revenus de l'entreprise en 2023, notamment le financement des fondations des National Institutes of Health (NIH) et de la recherche médicale privée.

Source de financement	2023 Montant
Subventions NIH	$375,000
Fondations de recherche privée	$250,000

Microbot Medical Inc. (MBOT) - Canvas Business Model: Value Propositions

You're looking at the core reasons why a hospital or interventional radiologist would choose Microbot Medical Inc.'s LIBERTY system over existing solutions. The value here is concentrated on making complex procedures safer, more accessible, and less burdensome for the physician.

First single-use, fully disposable endovascular robotic system. This is a major differentiator. Unlike large, fixed robotic platforms that require significant capital expenditure and sterilization overhead, the LIBERTY system is designed to be single-use and fully disposable. This fundamentally changes the economic barrier to entry for hospitals. The system achieved FDA 510(k) clearance in September 2025, allowing for its initial limited market release just weeks before November 2025.

Significantly reduced physician radiation exposure. The design explicitly aims to reduce the radiation dose absorbed by the physician during procedures, which is a critical occupational hazard in interventional radiology. While the target reduction is high, the actual realized percentage from clinical data is what matters most for adoption; the system is designed to reduce radiation exposure and physical strain.

Enhanced precision and control in complex endovascular procedures. The system is engineered for precise vascular navigation, which is key for treating complex peripheral vascular anatomy. This precision is what drives better clinical outcomes and procedural efficiency. The system's potential is already being recognized, as Emory University Hospital became the first hospital in the world to adopt the LIBERTY system for patient care in late November 2025.

Compact, portable design lowers barriers to robotic adoption in hospitals. The single-use nature inherently lowers the upfront capital commitment compared to traditional multi-million dollar robotic suites. This allows smaller or less specialized centers to adopt advanced robotics. The company ended Q3 2025 with $80.2 million in cash and investments to support this commercial rollout.

Potential to reduce contrast media use and improve patient safety. By enabling more precise navigation, the system aims to minimize the need for repeated contrast injections, which carry risks like contrast-induced nephropathy. This focus on safety is paramount for patient care improvements.

Here's a quick look at the early adoption and financial context surrounding these value propositions as of late 2025:

Metric Category	Value/Status	Date/Period	Source Context
First Adopter	Emory University Hospital	November 2025	First hospital to adopt for patient care
Regulatory Status	FDA 510(k) Cleared	September 2025	Cleared for peripheral endovascular procedures
Commercialization Phase	Limited Market Release Commenced	Late 2025	Full release planned for April 2026
Q3 2025 Net Loss	USD 3.58 million	Q3 2025	Compared to USD 3.22 million a year ago
Cash Position	$80.2 million	September 2025	Cash and investments on balance sheet
Enterprise Value	Approximately $83 million	Late November 2025	Reflecting market capitalization context
Current Ratio	27.5	Late November 2025	Reflecting robust short-term liquidity

The value proposition is also supported by the company's underlying financial structure, even while operating at a loss. For instance, the balance sheet showed total assets of $81.76M against liabilities of $3.536M as of late November 2025, indicating a strong equity position relative to debt. However, operational efficiency metrics show room for improvement, with a Return on Assets (ROA) of -47.96% and a Return on Capital LTM of -32.71%.

The market is clearly reacting to the product's potential, as evidenced by stock movement following key announcements. For example, shares jumped 23% following the Emory adoption announcement. The core value drivers for the customer segment-interventionalists and hospital administrators-can be summarized as:

• The only FDA cleared, single-use, remotely operated robotic system.
• Designed to reduce physician radiation exposure and physical strain.
• Enables precise vascular navigation in peripheral procedures.
• Strong liquidity with a Current Ratio of 27.5 supporting near-term operations.
• Net loss for nine months ended September 30, 2025, was USD 9.68 million.

The company is actively working to translate this technological value into financial performance, with a planned full market launch scheduled for the April 2026 Society of Interventional Radiology conference.

Microbot Medical Inc. (MBOT) - Canvas Business Model: Customer Relationships

You're looking at how Microbot Medical Inc. (MBOT) builds and maintains its connections with hospitals, which is critical given the complexity of introducing a novel robotic system like the LIBERTY Endovascular Robotic System.

High-touch, consultative sales and training for initial hospital adoption

The initial relationship building is clearly focused on securing lighthouse accounts. Microbot Medical Inc. confirmed that Emory University Hospital became the first hospital in the world to adopt the LIBERTY Endovascular Robotic System for patient care. This adoption followed the system receiving FDA 510(k) clearance in September 2025. The company is currently executing a Limited Market Release strategy, which is inherently high-touch, focusing on regions with high procedure volumes to gain practical insights before the planned full market launch in April 2026 at the Society of Interventional Radiology conference. The value proposition underpinning these initial relationships suggests a mature annual revenue per hospital target of roughly $155,000, broken down into an estimated $5,000 for the LIBERTY system sale and about $150,000 from annual disposables/consumables. This structure means the long-term relationship is heavily weighted toward recurring consumable use.

Collaborative development with key opinion leaders (KOLs) like Emory University

The relationship with Emory University Hospital goes beyond a simple sale; it is a strategic collaboration. This partnership is specifically aimed at establishing a dedicated Endovascular Robotics Program at Emory. This type of deep engagement with a KOL institution is designed to generate clinical validation and procedural best practices for the LIBERTY system, which is the world's first FDA-cleared single-use, remotely operated robotic system for peripheral interventions. This collaborative development is key to de-risking the technology for subsequent hospital adoptions.

Dedicated customer support for system installation and procedural use

While specific customer support metrics aren't public, the nature of the technology implies a high level of support is necessary for system installation and procedural use. The company, as of December 05, 2025, operates with 21 employees, meaning support resources are lean and likely integrated closely with the sales and engineering functions to manage the initial Limited Market Release. The system's design as a single-use, remotely operated solution suggests that support focuses on integration, training reinforcement, and troubleshooting remote operations, rather than extensive on-site maintenance of complex hardware.

Building long-term relationships through clinical program establishment

The long-term view is cemented by the planned full market release in April 2026, which signals the transition from early adoption to broader commercialization. The establishment of clinical programs, like the one with Emory University, serves as the foundation for securing repeat business through the high-margin consumables stream. The company ended September 2025 with $80.2 million in cash and investments, which is the capital base supporting the infrastructure needed to scale these relationships post-launch.

Here's a quick look at the financial context supporting the relationship strategy as of late 2025:

Metric	Value (as of late 2025)
Cash and Investments (September 2025)	$80.2 million
Employees (December 05, 2025)	21
Q3 2025 Net Loss	USD 3.58 million
Estimated Annual Consumables Revenue Per Hospital	$150,000
Planned Full Market Release Date	April 2026

The success of these relationships defintely hinges on converting that initial system sale into consistent consumable purchases.

Microbot Medical Inc. (MBOT) - Canvas Business Model: Channels

You're looking at how Microbot Medical Inc. (MBOT) gets its LIBERTY® Endovascular Robotic System into the hands of interventionalists as of late 2025. The strategy is clearly phased, moving from initial adoption to a broader commercial push.

Direct sales force targeting U.S. hospitals and interventional suites

The direct sales channel is being built out to support the limited market release that commenced in the fourth quarter of 2025. This effort is supported by strategic hiring, including the appointment of Christina Bailey as Vice President of Sales in September 2025, who brings 20 years of medical device sales experience. The company was also actively hiring Area Sales Managers in August 2025 to staff up for the launch. The initial target market for the U.S. commercialization is estimated at approximately 2.5 million peripheral endovascular procedures annually. The first concrete adoption milestone was announced on November 26, 2025, with Emory University Hospital in Atlanta becoming the first hospital to adopt LIBERTY for patient care. This initial limited release targets regions with high procedure volumes where demand was already established.

• VP of Sales hired: Christina Bailey.
• Initial U.S. market size target: 2.5 million annual procedures.
• First hospital adopter: Emory University Hospital.
• Limited Market Release start: Q4 2025.

Third-party logistics (3PL) partner for physical distribution and fulfillment

To ensure efficient execution of the launch, Microbot Medical Inc. secured a U.S.-based third-party logistics (3PL) company in October 2025. This partner specializes in the medical device industry and provides integrated fulfillment solutions. The arrangement allows Microbot Medical Inc. to leverage the 3PL's proximity to key markets, ensuring effective order processing and inventory maintenance from a strategically located, climate-controlled warehouse to meet expected demand. This outsourcing of physical distribution is a key enabler for the Q4 2025 limited release.

Here's a quick look at the logistical and launch milestones:

Channel Milestone	Date/Status (Late 2025)	Financial/Operational Detail
3PL Partnership Secured	October 2025	Supports inventory management and order processing.
Limited Market Release Start	Q4 2025	Precedes broader launch; supported by $80.2 million in cash/investments as of September 2025.
Broader Launch Event	April 2026	Planned to occur during the Society of Interventional Radiology conference.

Medical conferences (e.g., Society of Interventional Radiology) for product awareness

Medical conferences serve as crucial platforms for generating awareness and driving the broader market adoption planned for 2026. The company's CEO, Harel Gadot, presented the LIBERTY Endovascular Robotic System at the H.C. Wainwright Annual Investor Conference in September 2025. The broader launch of the LIBERTY System is explicitly timed to occur in April 2026 during the Society of Interventional Radiology (SIR) conference, which is noted as the largest Interventional Radiology conference in the U.S. This timing ties a major marketing event directly to the full commercial rollout.

Clinical publications and peer-reviewed data to drive adoption

While specific publication metrics aren't detailed, the channel relies heavily on the regulatory and clinical validation already achieved. The LIBERTY System is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures as of late 2025. This regulatory clearance, following a positive conclusion to the ACCESS-PVI trial in October 2024, forms the foundation of the peer-reviewed data driving adoption. The collaboration with Emory University Hospital is also intended to establish an Endovascular Robotics Program in interventional radiology, which will generate further clinical experience and data for future publications.

• Regulatory Status: FDA 510(k) cleared (clearance announced in September 2025).
• Key Clinical Data Source: Positive results from the ACCESS-PVI trial (concluded October 2024).
• Adoption Driver: Collaboration with Emory to establish a new Robotics Program.

Finance: review Q4 2025 cash burn projections against the $80.2 million cash position reported at the end of September 2025.

Microbot Medical Inc. (MBOT) - Canvas Business Model: Customer Segments

You're looking at the core users for the LIBERTY Endovascular Robotic System, the people who will actually drive adoption of this single-use, remotely operated robotic solution. Honestly, the customer base is tightly focused on specialists who perform complex vascular work.

Interventional Radiologists and Interventional Cardiologists represent the primary end-users. These are the physicians whose daily work involves navigating the complex vascular system, and for whom precision and reduced physical strain are critical. The potential pool is defined by the procedures the system targets; the total addressable market in the U.S. alone is estimated to encompass about 2.5 million annual peripheral endovascular procedures. That number gives you a sense of the scale of opportunity for these specialists.

The next layer is the facility itself: U.S. Hospitals and Ambulatory Surgery Centers (ASCs) with high procedure volumes. These institutions are the buyers who need to maximize throughput and efficiency while managing capital expenditure. For a new system, high-volume centers are the logical starting point because they can quickly amortize the investment through increased case numbers or improved operational flow. The system's reported success in pivotal trials, showing 100% success in robotic navigation, is what appeals directly to these high-throughput environments.

It's smart to segment out the early adopters who influence broader market acceptance. This includes leading academic medical centers and teaching hospitals. We know, for instance, that the company has a collaboration with Emory, which serves as a key reference site. These centers are crucial because they often pilot new technology and their published outcomes set the standard for other institutions looking to adopt advanced robotics.

Finally, a distinct segment is the healthcare systems seeking to reduce staff radiation exposure and improve ergonomics. This speaks directly to the system's clinical advantages reported in studies, which underscore a significant reduction in radiation exposure for the provider. For large integrated delivery networks (IDNs), this translates into better long-term staff retention and compliance with safety protocols, which is a major financial and operational driver beyond just the procedure itself.

Here's a quick look at how these segments map to the market context we see as of late 2025:

Customer Segment	Key Driver for Adoption	Relevant Market Context/Number
Interventional Radiologists & Cardiologists	Precision, Efficiency, Safety	U.S. TAM of approximately 2.5 million annual peripheral endovascular procedures.
High-Volume U.S. Hospitals & ASCs	Throughput, Operational ROI	The global surgical robotics market is growing at a 17.6% CAGR (2025-2030).
Leading Academic Centers (e.g., Emory)	Clinical Validation, Thought Leadership	Mentioned collaboration with Emory as a strategic partner.
Systems Focused on Staff Safety	Ergonomics, Radiation Reduction	Reported benefit of a significant reduction in staff radiation exposure.

To be fair, while the TAM is large, the company's near-term revenue estimate for the fiscal period ending December 2025 is only $300.00K, meaning penetration into these segments is just beginning. The focus right now is securing those initial high-profile accounts. Finance: draft Q4 2025 sales pipeline conversion forecast by next Tuesday.

Microbot Medical Inc. (MBOT) - Canvas Business Model: Cost Structure

You're looking at the cost side of Microbot Medical Inc. (MBOT) as they push the LIBERTY system toward broader adoption. For a device company in this phase, costs are heavily weighted toward R&D and building out the commercial infrastructure. Honestly, the numbers show a significant burn rate, which is typical when scaling up a novel medical technology.

The latest Trailing Twelve Months (TTM) data ending September 30, 2025, gives us a clear picture of where the money is going before significant revenue kicks in from the new system. The total operating expenses for the TTM period were $\mathbf{14.04}$ million USD, which resulted in an operating income of $\mathbf{-14.04}$ million USD for the same period.

Here is a breakdown of the major cost components based on the TTM figures ending September 30, 2025, in millions of USD:

Cost Category	TTM Amount (Millions USD)	Context/Comparison
Research & Development (R&D)	6.50	Historically around the $\mathbf{6.63M}$ mark annually
Selling, General & Administrative (SG&A)	7.54	Reflects commercial team build-out costs; higher than the historical $\mathbf{4.99M}$ estimate
Total Operating Expenses	14.04	The sum of reported operating expenses for the TTM period
Operating Income (Loss)	-14.04	The operating result for the TTM period ending September 2025

The SG&A figure of $\mathbf{7.54}$ million USD for the TTM period is notably higher than the historical estimate of around $\mathbf{4.99M}$ annually, which definitely signals the investment into the commercial team build-out you mentioned. The R&D spend at $\mathbf{6.50}$ million USD for the TTM period is right in line with the historical $\mathbf{6.63M}$ annual spend.

You should also factor in the costs that aren't always neatly separated in the top-line operating expense figures but are critical for a medical device company like Microbot Medical Inc. These are the non-R&D/SG&A drains on cash:

• Manufacturing and inventory costs for the disposable LIBERTY system.
• Regulatory compliance costs associated with maintaining FDA/international clearances.
• Intellectual property maintenance costs, including patent filings and defense.

To be fair, the negative operating income of $\mathbf{-14.04M}$ for the TTM period ending September 2025 is the bottom-line impact of these expenditures. The Q3 2025 net loss was $\mathbf{3.58}$ million USD. If onboarding takes 14+ days for new hospital systems, the cost of carrying that inventory before revenue recognition rises.

Finance: draft 13-week cash view by Friday.

Microbot Medical Inc. (MBOT) - Canvas Business Model: Revenue Streams

You're looking at the revenue generation plan for Microbot Medical Inc. (MBOT) as they transition from R&D to commercialization in late 2025. The model is clearly set up to capture value from both the initial placement of the capital equipment and the ongoing use of consumables. Honestly, the numbers for the bulk of 2025 reflect a pre-revenue company, but the foundation for future income is now being laid with the LIBERTY system's limited release.

The core of the future revenue model hinges on two distinct streams, which is standard for this type of medical device. Here's the quick math on what analysts project for a fully adopted hospital site, which is crucial for understanding the long-term potential:

Revenue Component	Projected Annual Value Per Hospital	Revenue Type
LIBERTY Capital Unit Sale	Approximately $5,000	One-time/Capital
Annual Disposables/Consumables	Approximately $150,000	Recurring
Total Annual Revenue (Mature Hospital)	Roughly $155,000	Blended

Sales of the LIBERTY Endovascular Robotic System capital unit.

This is the initial transaction when a hospital adopts the technology. Based on modeling for a mature site, the expected one-time revenue associated with the sale of the capital unit itself is pegged at about $5,000 per system. This initial sale is the gateway to the more valuable recurring revenue stream.

Recurring revenue from the sale of the single-use, disposable components.

This is where the sustained financial engine is expected to run. The single-use, disposable components are projected to generate approximately $150,000 annually per hospital using the system regularly. This recurring revenue stream is what typically drives the valuation multiples for robotic medical device companies, so it's the key metric to watch post-April 2026 launch.

Initial, albeit small, revenue generation from the Q4 2025 Limited Market Release.

Microbot Medical Inc. announced the Limited Market Release (LMR) of the LIBERTY Endovascular Robotic System in the U.S. in November 2025, following FDA clearance. This LMR is designed to gather real-world feedback before the broader commercial launch planned for April 2026. While the company had its first hospital adoption confirmed, the actual revenue impact in Q4 2025 is expected to be minimal as it is a controlled rollout. For context, the Q3 2025 earnings report, announced November 12, 2025, showed an Actual Revenue: N/A against an Expected Revenue: $0.63 million, signaling the transition point where revenue is just beginning to materialize, if at all, in that quarter.

Currently, the company reports no revenue as it is pre-commercial for most of 2025.

Up until the LMR, Microbot Medical Inc. was operating as a pre-commercial entity. Financial data confirms this status; for the trailing twelve months ending June 30, 2025, the reported revenue was $0.00. Furthermore, the six months ended June 30, 2025, showed a net loss of $6.1 million with no product revenues to date. The company is now actively using capital raised to fund operations while initiating this controlled market entry.

The revenue structure is therefore:

• Pre-LMR (Majority of 2025): Zero product revenue.
• Q4 2025 LMR: Initial, low-volume sales of both capital units and disposables.
• Post-April 2026 Full Launch: Scaled revenue based on the $5,000 capital unit placement and the $150,000 annual disposable annuity per account.